drug
(amlodipine besylate + indapamide + telmisartan)
Marketedupdated 3mo agoby Azurity Pharmaceuticals Inc
Approvedcommunity read0 votes
indications
investigational
Hypertension
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 5, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jan 23, 2038formulationUS 10322117
- Jan 23, 2038formulationUS 10799487
- Jan 23, 2038formulationUS 12465599
- Jan 23, 2038formulationUS 12465599
FDA exclusivities (3)
- Jun 5, 2028NPNP1.8y
- Jun 5, 2028NPNP1.8y
- Jun 5, 2028NPNP1.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that